TCHO: Does it need G-CSF – pro
Guidelins for any FG-CSF recommend it only if the regimen has a greater than 20% tidsk of rpiducing febrile neutropenia. Carboplatin/paclitaxel result in a very low incidence of grade 4 neutropenia. Febrile neutropenia was higher in TCH-P group 13% (3/23) versus 4.5% (1/22) in TCH group.
Hussain N, Said ASA, Khan Z. Safety Assessment of Neoadjuvant Pertuzumab Combined with Trastuzumab in Nonmetastatic HER2-Positive Breast Cancer in Postmenopausal Elderly Women of South Asia. Int J Breast Cancer. 2018 Apr
Markman J, Zanotti K, Webster K, Belinson J, Peterson G, Kulp B, Markman M.Experience with the management of neutropenia in gynecologic cancer patients receiving carboplatin-based chemotherapy. Gynecol Oncol. 2004 Feb;92(2):592-5.Hussain N, Said ASA, Khan Z. Safety Assessment of Neoadjuvant Pertuzumab Combined with Trastuzumab in Nonmetastatic HER2-Positive Breast Cancer in Postmenopausal Elderly Women of South Asia. Int J Breast Cancer. 2018 Apr